血清C反应蛋白在肝硬化腹水合并感染中的临床意义(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨血清C反应蛋白(CRP)在肝硬化腹水合并感染中的临床意义。 方法 检测106例肝硬化患者CRP、WBC和GR百分率(GR%)，计算合并感染和继发感染者各指标的阳性率。 结果 合并感染组和继发感染组CRP、WBC和GR%水平分别显著高于未合并感染组和无继发感染组(P<0.01)；合并感染组和继发感染组抗感染治疗后3 d和7 d，三者水平分别显著低于抗感染治疗前和治疗后3 d(P<0.01)。治疗前、治疗后3 d和治疗后7 d CRP阳性率均显著高于WBC和GR%阳性率(P<0.01)。 结论 检测CRP对肝硬化腹水患者感染的进展及抗感染疗效判断具有重要意义。
[关键词] 肝硬化；腹水；感染；C反应蛋白
[中图分类号] R575.2 [文献标识码] B [文章编号] 1673-9701(2012)01-054-02
Clinical significance of C reactive protein in liver cirrhosis patients complicating infection with ascites
WANG Xiao ZHU Junquan
Department of Laboratory Medicine, Zhejiang Provincial Shengzhou City People's Hospital, Shengzhou 312400, China
[Abstract] Objective To explore the clinical significance of serum C reactive protein(CRP) in liver cirrhosis patients complicating infection with ascites. Methods The levels of CRP, white blood cell (WBC) and granulocyte percent (GR%) in 106 patients with liver cirrhosis were determined, the positive percent was calculated in patients of infection-complicating and secondary infection. Results At infection-complicating group and secondary infection group, the levels of CRP, WBC and GR% were significantly higher than those at non-infection-complicating group and non-secondary infection group, respectively (P<0.01) After 3 and 7 days of anti-microbe therapy, the levels of CRP, WBC and GR% were remarkedly lower than those before therapy and after 3 days of therapy,respectively, at infection complicating group and secondary infection group (P<0.01). Before therapy，after 3 days and 7 days of therapy, the positive percent of CRP was markedly higher than that of WBC and GR% (P<0.01). Conclusions It is valuable for the change of CRP to evaluate the occlurence, development and therapeutical effect of infection in liver cirrhosis patients with ascites.
[Key words] Liver cirrhosis; Ascites; Infection; C reactive protein
肝硬化腹水患者由于肠源性因素及免疫功能低下，极易并发各种感染，是肝硬化患者死亡的重要原因之一[1]，因此，对感染及时有效的诊断以及抗感染治疗效果的有效判断尤为重要。为此，作者通过检测肝硬化腹水患者 的血清C反应蛋白(SCRP)水平，以了解其在肝硬化腹水患者合并感染中的临床意义，现报道如下。
1 资料与方法
1 ......
您现在查看是摘要介绍页，详见PDF附件(3028kb)。